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Cost-effectiveness of health care service
delivery interventions in low and middle
income countries: a systematic review
Samuel I. Watson*, Harvir Sahota, Celia A. Taylor, Yen-Fu Chen and Richard J. Lilford
Abstract
Background: Low and middle income countries (LMICs) face severe resource limitations but the highest burden of
disease. There is a growing evidence base on effective and cost-effective interventions for these diseases. However,
questions remain about the most cost-effective method of delivery for these interventions. We aimed to review the
scope, quality, and findings of economic evaluations of service delivery interventions in LMICs.
Methods: We searched PUBMED, MEDLINE, EconLit, and NHS EED for studies published between 1st January 2000
and 30th October 2016 with no language restrictions. We included all economic evaluations that reported incremental
costs and benefits or summary measures of the two such as an incremental cost effectiveness ratio. Studies were
grouped by both disease area and outcome measure and permutation plots were completed for similar interventions.
Quality was judged by the Drummond checklist.
Results: Overall, 3818 potentially relevant abstracts were identified of which 101 studies were selected for full text review.
Thirty-seven studies were included in the final review. Twenty-three studies reported on interventions we classed as
“changing by whom and where care was provided”, specifically interventions that entailed task-shifting from doctors to
nurses or community health workers or from facilities into the community. Evidence suggests this type of intervention is
likely to be cost-effective or cost-saving. Nine studies reported on quality improvement initiatives, which were generally
found to be cost-effective. Quality and methods differed widely limiting comparability of the studies and findings.
Conclusions: There is significant heterogeneity in the literature, both methodologically and in quality. This renders further
comparisons difficult and limits the utility of the available evidence to decision makers.
Keywords: Health service delivery, Economic evaluation, Service delivery intervention, Cost-effectiveness, Systematic
review
Background
Low and middle income countries (LMIC) face the high-
est burden of disease which they must tackle despite
severe resource limitations [1]. A key aspect of this is
ensuring that health services and the delivery of health
care are run in the most efficient way possible. This
includes deployment of the least expensive human
resources compatible with competent practice, for
example. However, the majority of economic evaluation
evidence concerns high income countries, [2] which is
unlikely to be generalizable to LMICs [3]. Furthermore,
while methods for the economic evaluation of patient-
level clinical interventions such as specific pharmaceuti-
cals have been well-developed and embedded into health
technology assessment in high income countries [4],
very limited evidence exists for service delivery interven-
tions. And again this mainly concerns high income
countries [5, 6].
A service delivery intervention can be conceived as sit-
ting between clinical interventions acting directly on the
patient and national or regional level policy interven-
tions [5]. More specifically, service delivery interventions
affect: to whom care is provided, and by whom; where
care is provided; information, communication and tech-
nology that enhance the care process; and improvements
to the quality and safety of care. Specific service delivery* Correspondence: s.watson.1@warwick.ac.uk
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interventions in LMICs include: task shifting from more
highly trained healthcare professionals to other health
workers with less training and fewer qualifications, such
as community health workers (CHWs); use of secondary
care providers in guideline dissemination to change out-
patient referral rates; outreach clinics, such as provision
of a night clinic for sex workers; and emergency care
quality improvement training [7]. We exclude financing
and governance arrangements, which are considered
policy-level interventions.
A number of previous and ongoing attempts have
been made to review and rank clinical interventions in
LMICs by cost-effectiveness [8–10]. A notable example
is the World Bank’s Disease Control Priorities in Devel-
oping Countries, which aims to identify the most effect-
ive and cost-effective interventions to tackle a wide range
of disease areas across LMICs. The discussion of cost-
effectiveness in these analyses is typically with respect to
whether or not to provide an intervention or treatment.
For example, provision of anti-retroviral therapy to prevent
mother-to-child transmission of HIV/AIDS or isoniazid
treatment for TB are widely considered cost-effective when
the comparator is no treatment [10]. However, knowledge
remains limited regarding the most cost-effective way to
organise the delivery of these interventions.
There is a growing volume of literature assessing
CHW programs. The use of CHWs has proven to be an
important service delivery innovation in low income
countries as they can provide basic health services at a
low cost. Recent systematic reviews of economic evalua-
tions of CHW programs have identified a number of
relevant studies [11, 12]. However, they concluded that
these were generally for the introduction of small, verti-
cal programs and not more relevant large scale,
horizontally-focussed initiatives. From an economic
perspective many of these studies were furthermore of
limited utility, because they did not include a measure
that integrated estimates of incremental costs and incre-
mental benefits, such as the expected net benefits or
incremental cost-effectiveness ratio (ICER), which is
required to inform resource allocation and service deliv-
ery decisions [13]. The review by Nkonki and colleagues
incorporated many studies that reported only costs or
average costs and average benefits [11]. There remains a
question around the evidence from ‘full’ economic evalu-
ations for service delivery interventions, including those
for CHW programmes.
In 2008, Lewin et al. conducted an overview of the evi-
dence of the effectiveness of service delivery interven-
tions in LMICs with the aim of “supporting the delivery
of cost-effective interventions.” They organised these
interventions into three categories: delivery arrange-
ments, governance arrangements, and financial arrange-
ments [7]. At the time the authors identified a lack of
high quality evidence in this area and did not consider
whether the interventions themselves were indeed cost-
effective. However, they provided a useful taxonomy and
definition of service delivery interventions, which we
make use of here to examine the published evidence on
their incremental cost-effectiveness or cost-benefit.
We aimed to review the use of health economic evalu-
ation for service delivery interventions in LMICs. There
is often considerable heterogeneity in study design be-
tween health economic evaluations, even for the same
intervention. Various forms of effectiveness evidence
may be incorporated, a wide variety of models may be
used to extrapolate to the endpoints of interest, and the
endpoints themselves may vary from disease specific
outcomes, such as cases of tuberculosis treated, to gen-
eric outcomes, such as disability adjusted life years
(DALY) averted. These differences may make it diffi-
cult for a decision-maker to discern which evidence is
relevant to them. There is therefore a strong need to
conduct systematic searches of studies in this area
and amalgamate and review them. The aims of this
article are fourfold. First, we aim to describe the
scope of economic evaluations in service delivery re-
search in LMICs. Second, to describe the quality of
the studies and to compare and contrast methods
used. Third, to summarise as far as possible the find-
ings from the studies. And fourth, to make recom-
mendations for policy and practice.
Methods
We conducted a systematic review of economic evalua-
tions of service delivery interventions in LMICs.
Definition of a service delivery intervention
There exists no universally accepted definition of a ser-
vice delivery intervention, which we discern to lie be-
tween clinical interventions and policy interventions in
their proximity to the patient. Acknowledging inevitable
overlap between intervention types, we considered (for
the purpose of this review) service delivery interventions
as those that could be judged as being classified in the
taxonomy specified by Lewin et al. as affecting ‘Delivery
arrangements’, but not financial and governance arrange-
ments, which were considered policy interventions [7].
Specifically, service delivery interventions affect: (i) to
whom care is provided and efforts made to reach them,
(ii) by whom care is provided, (iii) where care is pro-
vided, (iv) with what information and communication
and technology is care provided, and/or (v) how the
quality and safety of care is improved and monitored.
Search strategy
We adapted the search strategy from Lewin et al., who
conducted a systematic review of reviews of evidence of
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the effectiveness of service delivery interventions in pri-
mary health care in LMICs. To adapt this strategy we re-
moved terms pertaining specifically to reviews and
specifically to primary care. We added terms to identify
economic evaluations including cost-benefit analysis,
cost-effectiveness analysis, cost per DALY, cost*, eco-
nomic evaluation and so forth. The full search strategy is
available in the Supplementary Information. We
searched PUBMED, MEDLINE, EconLit, and NHS EED
for studies published between 1st January 2000, when
the millennium development goals were initiated, and
30th October 2016. There were no language restrictions.
LMICs were defined according to the World Bank [14].
This review was initiated as part of an internal project
and the protocol was submitted to and approved by the
medical school but was not registered with PROSPERO.
It is provided in the Supplementary Information. Each
abstract was reviewed independently by two reviewers.
Full text articles were obtained for all studies selected by
at least one reviewer. Disagreements about inclusion
were resolved through team discussion.
Inclusion criteria
Studies were included if: (i) it was an economic evalu-
ation that reported both incremental outcomes and in-
cremental costs. These included studies reporting
incremental cost-effectiveness ratios (ICER; e.g. cost per
case cured), incremental cost-benefit ratios (e.g. cost per
DALY), and expected incremental net benefit estimates
(net monetary value); (ii) the study examined a service
delivery intervention as defined above; (iii) the study
considered only intervention(s) implemented in a LMIC,
and (iv) the study was published between 1st January
2000 and 30th October 2016.
Exclusion criteria
Evaluations reporting only cost differences, effectiveness
estimates, or average costs or effects were excluded, in-
cluding cost-minimisation analyses. No restrictions on
language were applied.
Data extraction
The following data were extracted from each study
where reported: author(s); publication date; study date;
description of intervention(s) and comparator(s); study
country(ies); methods; source(s) of effectiveness evidence
and their sample size(s), unit of effectiveness, mean
age(s) of participants, and sex; source(s) of costs evi-
dence; mean and median costs for treatment and com-
parator and their differences and 95% confidence
intervals; currency; cost utility; cost benefit or cost-
effectiveness ratio and 95% confidence intervals or
expected net benefits; probability cost-effective; time
horizon, and perspective. HS extracted the data and SW
independently cross-checked the data against the ori-
ginal studies.
Quality assessment
The quality of the economic evaluations was judged
using the ten point Drummond checklist. [15] Each
study was scored independently by two authors (SW and
HS) out of a maximum of ten points. Disagreements
were resolved by discussion.
Synthesis and evaluation
Interventions were grouped according to the taxonomy
in Lewin et al. (Panel 1) discussed above [7]. Estimates
of ICERs or equivalent outcomes were grouped by both
disease area and outcome. Permutation plots were com-
pleted for interventions judged through discussion to be
similar and with similar comparators [16]. To aid com-
parability between results from different countries and
over different time periods, ICERs, or equivalent out-
comes, were converted into multiples of GDP per capita
for the relevant year and country. This also permits
comparability with World Health Organisation (WHO)
recommendations of cost-effectiveness thresholds; less
that one times GDP per capita per DALY averted is con-
sidered highly cost-effective and less than three times is
considered cost-effective [17]. GDP per capita was ob-
tained from the World Bank for the year of the relevant
study in nominal, purchasing power parity terms to en-
able comparability between studies of different years in
this metric. Where study year was not reported, publica-
tion year was used instead. A meta-analysis was not
deemed appropriate for these data, as service delivery in-
terventions are typically adapted to specific contexts,
and methods and data differ widely between studies.
Results
Studies included and excluded
Overall, 3818 potentially relevant abstracts were iden-
tified of which 101 studies were selected for full text
review. Sixty-five studies were excluded: 15 were con-
sidered clinical interventions and 10 were considered
policy (governance or finance) interventions, nine
studies were not economic evaluations; an incremen-
tal ratio or net benefits could not be calculated from
23 studies, two studies were not in an LMIC country,
and the remaining six did not report on a specific
intervention. In total, 36 full text articles were
included in the review (Fig. 1). The included studies
are reported in Table 1. The clinical topics covered
were HIV (ten studies), obstetric care (four studies),
child health (three studies), while the rest covered
other or multiple areas of care.
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Comparison of methods
The 36 included studies differed widely in terms of the
measures of effectiveness, perspective, time horizon, and
other methods. Table 2 details the methods and ap-
proaches used in the included studies. Nine studies were
economic evaluations alongside a randomised trial, while
the other studies were a mix of economic evaluations
from observational evidence or modelling studies. The
majority (21) of the included studies used basic arith-
metic approaches to calculate ICERs or equivalent,
the others used more complex model structures to
extrapolate from trial-based or other sources of evi-
dence. Most studies (26) reported conducting some
form of sensitivity analysis although only 13 con-
ducted probabilistic analyses.
As an illustration of methodological heterogeneity be-
tween studies, ten studies examined delivery interven-
tions for HIV/AIDS in Sub-Saharan Africa (Tables 1 and
2) [18–27]. None of these studies used the same effect-
iveness measures. Some used health outcomes: QALYs,
DALYs, ‘favourable’ immune response, life expectancy,
death rate, cases averted, and undetectable viral load.
The others used ‘surrogate’ endpoints: cases identified,
uptake of testing, patients retained, and “in care and
responding”. As shown in Table 2 eight of these ten
studies took a provider or health care perspective
[18–20, 22, 24–27] and two a societal perspective [21,
23]; the time horizon varied from less than one year
to 20 years; and only four included cost savings con-
tingent on reduced morbidity. This heterogeneity was
reflected across all the studies included in the review
rendering any further comparisons between studies
and interventions inappropriate.
Comparison of study quality
Quality scores varied widely according to the Drummond
ten point checklist. Scores ranged from three to ten out of
ten (Table 1). Aside from the difficulties with comparability
between studies, the most common weaknesses in the
included studies were the establishment of effectiveness
evidence (question 3: 17/36 studies meeting the criterion)
and the credible valuation of costs and consequences (ques-
tion 6: 21/36 studies). Poor reporting also prevented deter-
mination of whether criteria were met. As reported in
Table 2, it was not possible to establish discount rates for a
number of studies (Question 7: 14/36 studies); discount
rates were potentially not reported for short time horizons,
but may have still been required for the valuation of capital.
Fig. 1 PRISMA diagram
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Assessment of task shifting interventions
The most widely studied types of delivery intervention
were ones that altered “by whom and where” care was pro-
vided. We classified 11 and 12 of the 36 included studies
in these categories, respectively. The predominant focus of
these interventions was provision of typically doctor-led
care by nurses or CHWs (eight studies [18, 19, 28–33]), or
shifting place of care, such as providing treatment at home
or in the community instead of at a facility (12 studies
[20–26, 34–38]). The remaining three studies compared
guardian to CHW supervised treatment for TB [39], in-
creasing midwifery staffing, [40] and an integrated
community-based programme for infectious disease (as
compared to standard facility based care) [41].
Twenty of these 23 studies evaluated shifting care to
potentially less costly settings: specifically either from
doctors to nurses or CHWs, or from a facility to the
home or community. Nine of these 20 reported the in-
cremental cost per DALY averted or cost per QALY
gained so that the results could be compared to WHO
thresholds [20, 24, 29–31, 35–37, 41]. Seven of these nine
that reported DALYs were considered highly cost-effective
or cost-saving, i.e. less costly and at least as effective, when
compared to WHO thresholds. A further three of the 20
studies were likely to be considered cost-effective on the
basis of life years saved [23, 32, 38], and four more studies
reporting other effectiveness outcomes were estimated to
be cost-saving overall compared to a relevant alternative
[18, 22, 28, 33]. Fig. 2(a) shows a permutation plot of the
20 studies examining shifting care to potentially less costly
settings grouped by their estimated changes to costs and
health outcomes and the resulting implications for deci-
sion makers. Taken together the evidence suggests that
shifting tasks from doctors to CHWs, nurses, and/or from
facility into the community is likely to be cost-effective
and even potentially cost-saving.
Assessment of quality improvement interventions
Nine studies reported an economic evaluation of a qual-
ity improvement initiative. Their incremental costs and
a
b
Fig. 2 Permutation plots summarising the number of economic evaluations according to their findings. Numbers in cells represent
numbers of studies. a Shifting care to less costly settings: Community based care or task shifting versus facility based or doctor-led
care. b Quality improvement: QI initiatives for community, primary, and secondary care
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benefits are summarised in Fig. 2(b) [27, 42–49]. Five of
these examined quality improvement in health care facil-
ities, all of which were considered highly cost-effective
[43, 45–48]. These schemes were comprised typically of
staff training and improved supervision. Medical equip-
ment and quality assurance was also included in two of
these studies [46, 47]. Beyond quality improvement ini-
tiatives in formal health care facilities, one study com-
pared high and low staff to patient ratios, but did not
find that well-staffed HIV clinics were cost-effective
compared to the standard care with lower staff-patient
ratios [27]. A large rural primary care quality improve-
ment initiative in Ethiopia that implemented and im-
proved community and primary care infrastructure,
funding, and services simultaneously also failed to dem-
onstrate cost-effectiveness [46]. However, drug safety
training for drug-dispensing shopkeepers was estimated
to be highly cost-effective in Uganda [42]. This latter
finding reflects the results from similar, non-quality fo-
cussed initiatives included in the review but classified in
other categories, such as interventions to improve the
knowledge of lay trauma first-responders in Uganda
[32], and providing cardio-vascular disease training to
CHWs in South Africa [29]. Taken altogether there ap-
pears to be good evidence that quality improvements
through training and supervision are highly cost-
effective. Only four quality improvement studies ap-
peared to take into account cost-savings to the health
service contingent on reduced morbidity [43, 45, 47, 49].
Assessment of other types of service delivery intervention
There were four further studies included in the review
that examined a range of different interventions. Two
considered information and communication technology
interventions for hospitals, one in China [50] and one in
India [51]. Two articles considered interventions
expanding helminth control programs: one to schools
[52] and the other to the whole community [53]. All four
of these interventions were estimated to be cost-effective
or cost-saving.
Discussion
For two broad classes of intervention identified in this
review the evidence suggests that they are cost-effective
or potentially cost-saving. Firstly, shifting basic care from
facilities to the community or the home, or from doctors
to nurses or CHWs has been shown to be cost-effective
across a broad range of conditions. Testing, counselling,
and management of HIV at home was generally more
costly but also more effective than doing so in facilities.
Similarly, involving and training lay members of the
community in emergency care, CVD management, and
mental health all proved cost-effective. However, the task
shifting programs were generally small-scale, local
initiatives by researchers or healthcare providers, Further
evidence is required to assess these interventions at
scale. Secondly, quality improvement initiatives in
community, primary, and secondary care involving
staff training, supervision, and equipment upgrades
were also generally considered cost-effective. However,
the significant heterogeneity in the design and report-
ing of the economic evaluations rendered more spe-
cific quantitative comparisons of results between
interventions inappropriate.
A key purpose of economic evaluation is to inform de-
cisions. But even within the same disease area in the
same region, a decision maker would have difficulty syn-
thesising the available studies to come to an informed
decision on the basis of the studies reviewed here. For
example, service delivery interventions for HIV in Sub-
Saharan Africa used a wide range of different outcomes,
perspectives, methods, and time horizons. Without
knowledge of how the results compare in terms of gen-
eral cost-effectiveness measures, such as a cost per
DALY, a decision maker would not be able to choose
from among the many similar but ultimately mutually
exclusive alternative organisational arrangements. There
is a strong case for a more standardised way of conduct-
ing and reporting economic evaluations in this area,
while respecting the differences between context-specific
interventions. This is a key area for future research and
reporting guidelines.
Lewin and colleagues studied service delivery research
across LMICs ten years ago and noted a ‘dearth of evi-
dence in low and middle income countries’ [7]. More re-
cent reviews of service delivery interventions, such as
CHW programs, [11, 12] show that the evidence base is
growing in this area. Nevertheless, these recent reviews
of CHW programs and the results presented here dem-
onstrate that there is still insufficient good quality evi-
dence to support policy makers’ decisions in this area.
The subject is clearly still at an early stage of develop-
ment and the time is propitious to influence the devel-
opment of the field.
There is no clear line that delineates service delivery
interventions from policy or clinical interventions.
Rather these interventions exist on a spectrum. A clin-
ical intervention is applied directly to a patient whereas
a service delivery intervention is applied to the organisa-
tion of a clinical intervention and its delivery [5]. As
such, there may be some disagreement with regard to
the eligibility of studies selected for inclusion here, for
example, whether the extension of helminth control pro-
grams or public health behavioural change interventions
are service delivery interventions. Governance and
finance arrangements were excluded as they were
classed as policy interventions and concern decision
makers at a different level. For example, we excluded an
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economic evaluation of a private sector capitation model
for the public sector for diabetes in South Africa [54].
The economic evaluation of health care policy in LMICs
is important for effective decision making on health care
organisation and should be the subject of future
research. We did not formally consider publication bias
given the lack of an agreed method to do so for eco-
nomic evaluations. It is possible that there is a bias
towards publishing results that appear cost-effective, or
that economic evaluations are undertaken only for inter-
ventions thought to be effective. This is another import-
ant area for future research.
The design and organisation of health services is a
growing and important issue. The severe resource limi-
tations in many LMICs necessitate high quality eco-
nomic evaluation. Guidelines and data resources for
economic evaluation in LMICs such as WHO Choice
are available [55]. However, there is a high level of meth-
odological heterogeneity between studies in LMICs and
when compared to studies in high income countries.
This may be due to levels of health economics research
capacity or different expectations of funders, journals, or
peer reviewers [56]. Previous research has also demon-
strated the wide differences in results from different
approaches, such as between top-down and bottom up
costing approaches [57]. A key recommendation of this
study is therefore standardisation of research methods
and ensuring adherence to reporting guidelines. This
can be achieved by funders, journals, and policy makers.
Standardising outcomes may be hindered by data limita-
tions, although DALY values for many diseases are pub-
lished, such as by the Global Burden of Disease studies
[58]. Other studies have emphasized the need for broad
measures of general health and well-being to both cap-
ture benefits across multiple dimensions and ensure
comparability between studies [59].
Conclusions
There is a large evidence base supporting effective and
cost-effective treatment of the diseases afflicting LMIC
such as HIV, TB, and malaria. However, the evidence
supporting the optimal configuration of services is highly
limited and is an important direction for future research.
Available evidence generally supports shifting care to
less costly settings, such as in the community instead of
a health care facility, or task shifting from doctors to
CHWs. Quality improvement initiatives were generally
found to be more costly and more effective. However,
there is significant heterogeneity in the literature, both
in methodological approaches and in quality. This ren-
ders further comparisons difficult and limits the utility
of the available evidence to decision makers. Given the
severe resource limitations in LMICs, there is a pressing
need for high quality economic evaluation of service
delivery interventions and a need for standardisation of
methods and reporting to facilitate its use to decision
makers.
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